Cagent Vascular Showcases Serration Remodeling Therapy at Major Vascular Symposium

According to a recent LinkedIn post from Cagent Vascular Inc, Dr. Frank Arko presented on peripheral artery disease (PAD) at the Charing Cross Symposium 2026, focusing on the issue of elastic recoil in endovascular treatment. The post highlights the company’s Serration Remodeling Therapy (SRT) as a potential approach aimed at delivering more predictable and durable patient outcomes.

The post suggests that positioning SRT as a “new standard of care” could signal Cagent Vascular’s intent to expand clinical adoption and differentiate its technology within the vascular intervention market. For investors, increased visibility at a major international vascular forum may support physician awareness, procedure volumes, and longer-term revenue potential if clinical data and reimbursement environments ultimately align with this positioning.